Marshall Wace’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

Marshall Wace’s Portfolio RVLP Stock Details RVLP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-11,300	Closed	-$24K	–	3611
2022 Q3	$24K	Buy	+11,300	New	+$22K	﹤0.01%	3259
2021 Q3	–	Sell	-57,958	Closed	-$174K	–	3552
2021 Q2	$174K	Sell	57,958 -39,607	-41%	-$121K	﹤0.01%	2471
2021 Q1	$318K	Hold	97,565	–	–	﹤0.01%	2109
2020 Q4	$402K	Sell	97,565 -190,132	-66%	-$1.1M	﹤0.01%	1567
2020 Q3	$1.56M	Buy	287,697 +65,689	+30%	+$378K	0.01%	879
2020 Q2	$1.5M	Sell	222,008 -103,329	-32%	-$506K	0.01%	887
2020 Q1	$1.03M	Buy	325,337 +274,739	+543%	+$1.46M	0.01%	795
2019 Q4	$354K	Buy	+50,598	New	+$270K	﹤0.01%	1240

Other funds holding RVLP

ACM

Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return

Rovida Advisors Fort Lauderdale, Florida $116M AUM 12.52% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace's RVLP Position: Q4 2022 in Review

Marshall Wace sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q4 2022, closing a stake of 11,300 shares — an estimated $24K sold.

Marshall Wace first reported a position in RVLP in Q4 2019 and held it in 8 quarters. The position peaked at $1.56M in Q3 2020. 36 funds tracked by Wall St. Rank hold RVLP as of Q4 2022.

Marshall Wace reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Marshall Wace sold 11,300 RVL Pharmaceuticals plc Ordinary Shares shares in Q4 2022, an estimated $24K.
Marshall Wace first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q4 2019 and held it in 8 quarters.
Marshall Wace's RVL Pharmaceuticals plc Ordinary Shares position peaked at $1.56M in Q3 2020.
36 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q4 2022.

Based on Marshall Wace's 13F filing for Q4 2022, filed 14 Feb 2023.